Study of Tau PET Outcomes in Patients Receiving Anti-amyloid Immunotherapies
试验速览
- 阶段
- 2 期
- 状态
- Enrolling By Invitation
- 发起方
- Mayo Clinic
- 入组人数
- 135
- 试验地点
- 1
- 主要终点
- Change in tau PET Standardized Uptake Value (SUVR)
研究概览
简要总结
This is an imaging study of patients with mild Alzheimer's disease receiving amyloid-targeting therapy and under the care of neurologists at Mayo Clinic in Rochester, MN.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Treatment Group
Subjects with a diagnosis of mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease and amyloid positive, who are starting anti-amyloid immunotherapy.
干预措施: 18F-AV-1451 (Drug)
结局指标
主要结局
Change in tau PET Standardized Uptake Value (SUVR)
时间窗: Baseline, 18 months
A PET Standardized Uptake Value (SUV) is measured by calculating the ratio of the radioactivity concentration within a specific region of interest (ROI) on a PET scan, divided by the injected dose of the radiotracer per unit of the patient's body weight. The calculated Standardized Uptake Value (SUVR) is reported as a single number, with higher values indicating greater tracer uptake in the target region relative to the reference region
次要结局
- Number of subjects to develop amyloid-related imaging abnormalities (ARIA)(18 months)
研究者
Petrice M. Cogswell
Principal Investigator
Mayo Clinic